Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoyoujiedu is a Traditional Chinese Medicine (TCM) prescription currently under clinical investigation for its therapeutic potential in advanced non-small cell lung cancer (NSCLC). It is being studied in combination with PD-1 monoclonal antibody and chemotherapy, with a particular focus on its sensitization mechanism to enhance the efficacy of these conventional treatments. The name "消癌解毒方" (Xiao'ai Jiedu Fang) translates to "Cancer Elimination and Detoxification Formula," suggesting its intended properties include clearing heat, detoxifying, and inhibiting cancer growth. Research indicates that this TCM prescription may exert its anti-tumor effects by inhibiting tumor cell proliferation, inducing apoptosis, regulating the immune microenvironment, and potentially inhibiting tumor angiogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiaoyoujiedu.